| 1.565 -0.005 (-0.32%) | 12-05 10:02 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.9 | 1-year : | 2.22 |
| Resists | First : | 1.62 | Second : | 1.9 |
| Pivot price | 1.36 |
|||
| Supports | First : | 1.36 | Second : | 1.2 |
| MAs | MA(5) : | 1.46 |
MA(20) : | 1.36 |
| MA(100) : | 1.68  |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 92 |
D(3) : | 78.2 |
| RSI | RSI(14): 58.9 |
|||
| 52-week | High : | 2.79 | Low : | 1.1 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AUTL ] has closed below upper band by 3.5%. Bollinger Bands are 10.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.61 - 1.61 | 1.61 - 1.62 |
| Low: | 1.44 - 1.45 | 1.45 - 1.46 |
| Close: | 1.56 - 1.57 | 1.57 - 1.58 |
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Tue, 02 Dec 2025
Autolus Therapeutics Appoints Ryan Richardson to Board - TipRanks
Mon, 01 Dec 2025
Ryan Richardson joins Autolus Therapeutics board of directors By Investing.com - Investing.com Nigeria
Mon, 01 Dec 2025
Autolus Therapeutics plc Appoints Ryan Richardson to Board of Directors - marketscreener.com
Mon, 01 Dec 2025
Autolus Therapeutics (Nasdaq: AUTL) adds ex-BioNTech strategy chief Ryan Richardson to its Board of Directors - Stock Titan
Tue, 25 Nov 2025
Autolus Therapeutics Boosts Market Confidence with Promising Data at American Society Meeting - StocksToTrade
Tue, 25 Nov 2025
Is Autolus Therapeutics PLC (AUTL) One of the Fastest-Growing Penny Stocks to Buy Now? - Finviz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 266 (M) |
| Shares Float | 111 (M) |
| Held by Insiders | 18 (%) |
| Held by Institutions | 73 (%) |
| Shares Short | 11,660 (K) |
| Shares Short P.Month | 11,820 (K) |
| EPS | -0.83 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1 |
| Profit Margin | 0 % |
| Operating Margin | -338 % |
| Return on Assets (ttm) | -23 % |
| Return on Equity (ttm) | -60.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.51 |
| Sales Per Share | 0.19 |
| EBITDA (p.s.) | -1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -254 (M) |
| Levered Free Cash Flow | -268 (M) |
| PE Ratio | -1.88 |
| PEG Ratio | 0 |
| Price to Book value | 1.55 |
| Price to Sales | 8.12 |
| Price to Cash Flow | -1.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|